MedTrace Logo

Neoadjuvant Therapy for Locally Advanced Rectal Cancer With Fruquintinib, Toripalimab and SRT

NCT05763927 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2023-03-10

No results posted yet for this study

Summary

The purpose of this study is to investigate the efficacy and safety of combined fruquintinib、toripalimab and SRT in neoadjuvant therapy for locally advanced rectal cancer.

Conditions

Interventions

DRUG

Fruquintinib

Fruquintinib 5mg 2w on/1w off, 21d/cycle, totally 4 cycle.

DRUG

Toripalimab

Toripalimab 200mg d1, 21d/cycle, totally 4 cycle.

RADIATION

Short-course radiotherapy

25 Gy in 5 fraction, d22-26.

PROCEDURE

TME

Surgical resection of the primary tumour in the rectum, 2-4weeks after the last dose of fruquintinib

Sponsors & Collaborators

  • West China Hospital

    lead OTHER

Principal Investigators

  • Shared for: scientific research institutions, academic journal Shared for: scientific research institutions, academic journal, MD · West China Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-01
Primary Completion
2024-10-01
Completion
2025-04-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05763927 on ClinicalTrials.gov